Compass Pathways reports six-month durability of response in pivotal psilocybin depression trial

Compass Pathways announced that patients in the second of its two pivotal psilocybin trials for depression continued to show a therapeutic response for at least six months. The durability data suggest that the benefit of the treatment is sustained over time, a key factor for regulatory approval.

The company said the findings keep it on schedule to complete its New Drug Application filing before the end of the year. Maintaining response durability is a critical milestone as the therapy moves toward potential market entry.

The update was presented by CEO Kabir Nath and underscores the progress of the program as it advances through late-stage development.